BlackBarn Capital Partners LP: AMNEAL PHARMACEUTICALS INC (AMRX): Quarterly 13F Position History
As of Q1 2026, BlackBarn Capital Partners LP reported 1,650,000 shares of AMNEAL PHARMACEUTICALS INC (AMRX), worth $20.5M and representing 6.2% of its 13F equity book. Quarter-over-quarter share count change: + 80,000 (+5.1%) . The position first appeared in Q1 2024 and has been disclosed across 9 13F-HR filings in Pactolio's tracked window.
- 1,650,000Shares Held (Latest Filing)
- $20.5MReported Market Value (Latest Filing)
- 6.2%Portfolio Weight (% of 13F Equity Book)
- +80,000Quarter-over-Quarter Share Change
- +$727.5KQuarter-over-Quarter Value Change
- 3,446,570Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 9 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 1,650,000 | +80,000 | +5.1% | $20.5M | 6.2% | $12.4 |
| Q4 2025 | 1,570,000 | 619,452 | -28.3% | $19.8M | 7.1% | $12.6 |
| Q3 2025 | 2,189,452 | 1,257,118 | -36.5% | $21.9M | 7.2% | $10.0 |
| Q2 2025 | 3,446,570 | +564,916 | +19.6% | $27.9M | 9.2% | $8.1 |
| Q1 2025 | 2,881,654 | +31,654 | +1.1% | $24.1M | 8.2% | $8.4 |
| Q4 2024 | 2,850,000 | +438,388 | +18.2% | $22.6M | 8.9% | $7.9 |
| Q3 2024 | 2,411,612 | +411,612 | +20.6% | $20.1M | 8.7% | $8.3 |
| Q2 2024 | 2,000,000 | +586,703 | +41.5% | $12.7M | 6.5% | $6.3 |
| Q1 2024 | 1,413,297 | — | — | $8.6M | 5.0% | $6.1 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did BlackBarn Capital Partners LP first disclose a AMRX position in 13F-HR filings?
BlackBarn Capital Partners LP first reported AMNEAL PHARMACEUTICALS INC (AMRX) on its 13F-HR filing for the period ending 2024-03-31 (Q1 2024). The position has appeared on 9 reported quarters within Pactolio's tracked window.
What was BlackBarn Capital Partners LP's most recent quarter-over-quarter share-count change in AMRX?
Between Q4 2025 and Q1 2026, BlackBarn Capital Partners LP added 80,000 shares of AMRX (+5.1%), bringing the total reported position to 1,650,000 shares at a market value of $20.5M.
Does the implied price-per-share represent BlackBarn Capital Partners LP's cost basis in AMRX?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.